|
|
(21 intermediate revisions by 3 users not shown) |
Line 48: |
Line 48: |
| [[User:Michael|Michael]] ([[User talk:Michael|talk]]) 23:43, 25 October 2014 (EDT) | | [[User:Michael|Michael]] ([[User talk:Michael|talk]]) 23:43, 25 October 2014 (EDT) |
|
| |
|
| == Short answer questions on genetics and molecular pathology. == | | = [[Short answer questions submitted by Tate]]= |
| | |
| These are some questions I came up with that are plausible to me... let me know if they are out to lunch.
| |
| | |
| UNIT 1
| |
| {{hidden|1. List three differences between DNA and RNA.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|2. What are the three stop codons?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|3. Where does transcription begin?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|4. List three enzymes necessary for transcription and their function. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|5. List and describe four post transcription modifications of RNA.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|6. List three differences between somatic and germline mutations. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|7. What is the difference between a missense and a non-sense mutation?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|8. Define a frameshift mutation. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|9. Why are inversion mutations difficult to detect?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|10. Describe the potential sequelae of a translocation mutation. |<center>[[Microsatellite instability]]</center>}}
| |
| | |
| UNIT 2
| |
| {{hidden|1. Translate the following: c.1524_1527delCGTA.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|2. List 5 features of SNPs.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|3. Define a regulatory SNP and a synonymous SNP?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|4. What is the difference between a microstalellite and a minisattelite?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|5. Describe Hardy-Weinberg Equilibrium?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|6. What factors can disrupt the H-W equilibrium?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|7. What is linkage disequilibrium?|<center>[[Microsatellite instability]]</center>}}
| |
| | |
| UNIT 3
| |
| {{hidden|1. What are the three major steps of PCR?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|2. What is the hallmark of PCR?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|3. What factors affect the method of genotyping chosen?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|4. Define sensitivity, specificity, positive predictive value and negative predictive value. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|5. Define reproducibility and accuracy of an analytical test. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|6. Describe briefly Sanger sequencing.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|7. Describe briefly how Taqman automated genotyping is used for allele detection. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|8. How are DNA microarrays used to identify drug disposition or responses?|<center>[[Microsatellite instability]]</center>}}
| |
| | |
| UNIT 4
| |
| {{hidden|1. Describe the procedure for submitting FFPE slides for KRAS for colorectal cancer.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|2. Compare and contrast uniplex versus multiplex genotyping. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|3. Compare and contrast conventional vs massively parallel sequencing. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|4. What is multiplex ligation-dependent ligation (MLPA)?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|5. What is fragment analysis?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|6. Compare and contrast RT-PCR vs qRTPCR.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|7. What is MSI?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|8. What is methylation analysis?|<center>[[Microsatellite instability]]</center>}}
| |
| | |
| UNIT 5
| |
| {{hidden|1. What are the four test features required to be documented by the CLIA?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|2. What are "in vitro diagnostics" vs "laboratory developed tests"?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|3. What does validation mean? |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|4. What are the four performance characteristics that need to be verified for FDA cleared/approved tests?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|5. What are the six performance characteristics that need to be verified for FDA cleared LDTs or modified FDA cleared/approved tests?|<center>[[Microsatellite instability]]</center>}}
| |
| | |
| UNIT 6
| |
| {{hidden|1. List the components of a molecular pathology report.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|2. Define analytical sensitivity and clinical sensitivity. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|3. What should be said in a report of a molecular test on a patient for residual disease if no previous positive assay was confirmed?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|4. Define ammended report versus addendum report.|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|5. Whose responsibility is it to sythesize the test results with other clinico-pathological information?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|6. How long are cytogenetic reports required to be kept by CAP?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|7, What is the recommended process to use test results if an assay is not yet validated for clinical use?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|8. Give three examples of "grey areas" which warrant discretion of professionals involved to use a non-validated test?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|9. What reference standard is available for gene nomenclature?|<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|10. Create a table of the most common gene rearrangements associated with heme and soft tissue diseases. |<center>[[Microsatellite instability]]</center>}}
| |
| {{hidden|11. What is a "DNA fingerprint" and what can it be used for?|<center>[[A method that examines multiple areas of short tandem repeats to identify paternity, mosaicism, chimerism, and identity in forensics cases]]</center>}}
| |
| | |
| | |
| Robbins and Cotran Chapter 5 9th Edition:
| |
| | |
| {{hidden|MC cause of spontaneous abortion is ?|<center>[[ A demonstrable chromosomal abnormality.]]</center>}}
| |
| | |
| {{hidden|1% of all newborn infants possess a gross chromosomal abnormality and 5% of people <25y present with |<center>[[a genetic disease. ]]</center>}}
| |
| | |
| {{hidden|Mutation|<center>[[permanent change in the DNA, if affect germ cells are transmitted to the progeny ]]</center>}}
| |
| | |
| {{hidden|List and describe 4 broad categories of human genetic disorders:|<center>[[Disorders related to mutation sin single genes with large effects i. Usually follow classic Mendelian pattern of inheritance
| |
| ii. Often highly penetrant (large proportion of pop with gene has disease)
| |
| b. Chromosomal disorders
| |
| i. Structural or numerical alterations in autosomes and sex chromosomes
| |
| ii. Uncommon, high penetrance
| |
| c. Complex multigenic disorders
| |
| i. Interactions between multiple variant forms of genes and environmental factors (polymorphisms), poly genic means disease when many polymorphism present
| |
| d. Single gene disorders with nonclassic patterns of inheritance (not mendelian)
| |
| i. Disorders resulting from triplet repeat mutations
| |
| ii. Mutations in mitochondrial DNA
| |
| iii. Those influenced by genomic imprinting
| |
| iv. Those influenced by gonadal mosaicism]]</center>}}
| |
| | |
| {{hidden|List and describe the possible outcomes of a point mutation in a coding region?|<center>[[a. Missense mutation – pt mutation changes amino acid code, conservative when the amino acid is preserved, non conservative when replaced with another amino acid
| |
| b. Nonsense mutation – makes a stop codon ]]</center>}}
| |
| | |
| {{hidden|List and describe the possible outcomes of point mutation or deletion in a non-coding region.|<center>[[a. Promoters/enhancers – interfere with binding of transcription factors, marker reduction or total lack of transcription, b. Introns – defective splicing > failure to make mature RNA > no translation]]</center>}}
| |
| {{hidden|List and describe the possible outcomes of deletions and insertions.|<center>[[a. Small coding: not multiple of three = frameshift, if multiple of 3 than add or del amino acids accordingly, often premature stop codon
| |
| i. Tay Sachs disease: 4 base pair insertion in Hexosaminidase A gene
| |
| {{hidden|List and describe the possible outcomes of trinucleotide repeat mutations.
| |
| a. Usually G&C, dynamic and increase during gametogenesis, “RNA stutters”
| |
| b. Fragile X – CGG 250-4000, Huntinton’s Disease * See Neuropath Notes
| |
| {{hidden|List and describe three examples of inheritance of single gene mutations
| |
| a. AD – manifested in the heterologous state, one parent of index case is usually affected, males and females affected and both can transmit condition
| |
| i. De novo cases may not have affected parent
| |
| ii. Penetrance = fraction of people with gene who have the trait
| |
| iii. Variable expressivity = those with mutant gene have variety of phenotypes
| |
| iv. Often age of onset is delayed so can reproduce before die from disease
| |
| v. Biochem mechanisms
| |
| 1. Reduced production of a protein or dysfunctional/inactive protein
| |
| 2. Involved in regulation of complex metabolic pathyway subject to feedback inhibition
| |
| 3. Key structural proteins (collagen and cytoskeleton of RBC)
| |
| a. May be a dominant negative , e.g. osteogenesis imperfecta
| |
| 4. Gain of function are rare, 2 forms
| |
| a. Increased in proteins normal function (excess enzyme activity)
| |
| b. Huntinton’s diseas (abn protein accumulates, toxic to neurons)
| |
| b. AR
| |
| i. Largest category – both alleles at a locus are mutated
| |
| 1. Expression is uniform, complete penetrance common, early onset, unaffected carrier family members, mostly enzymes
| |
| c. X Linked
| |
| i. All sex linked, and almost all are recessive , if Y Chromosome affected usually infertile males > no progeny
| |
| ii. Male expression b/c hemizygous, daughter carriers with variable phenotype because of lionization of 2nd X e.g G6DP
| |
| iii. Dominant . vitamin D resistant rickets]]</center>}}
| |
| Stopped at P142
| |
| | |
| Molecular Genetic Diagnosis
| |
| 1. List three basic molecular diagnostic techniques
| |
| a. Karyotyping
| |
| b. Southern blot
| |
| c. Sanger DNA sequencing
| |
| d. Polymerase chain reaction
| |
| 2. Constitutional vs somatic mutaitons.
| |
| Hi Michael, I've started, but mostly just with the questions for now, as I study I will keep working on it. Can you help me, maybe we can make additional discussion pages for each of my "study" exams,e.g. molecular, robbins chapters, cap protocols etc.
| |